Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 9/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.64 |
| ▸ | XDH | P47989 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8860537 | 0.90 | PTGS1 (0.64) | PTGS1PTGS2XDHHIF1AEPAS1 | |
| SCHEMBL8860175 | 0.86 | XDH (0.61) | PTGS1PTGS2XDHHIF1AEPAS1 | |
| SCHEMBL29403680 | 0.83 | PTGS1 (0.80) | PTGS1PTGS2XDHHIF1AEPAS1 | |
| SCHEMBL16226550 | 0.80 | XDH (0.70) | PTGS1PTGS2XDHHIF1AEPAS1 | |
| SCHEMBL8860230 | 0.80 | XDH (0.67) | PTGS1PTGS2XDHHIF1AEPAS1 | |
| Ustilaginoidin A SCHEMBL3119631 | 0.79 | PTGS1 (0.62) | PTGS1PTGS2XDHHIF1AEPAS1 | |
| SCHEMBL30105701 | 0.77 | CYP3A4 (0.69) | PTGS1PTGS2XDHHIF1AEPAS1 | |
| Stellatin SCHEMBL29368317 | 0.76 | PTGS1 (1.00) | PTGS1PTGS2XDHKDM4EMAPT | |
| SCHEMBL8860458 | 0.76 | PTGS1 (0.48) | PTGS1PTGS2XDHHIF1AEPAS1 | |
| Rubrofusarin SCHEMBL486101 | 0.75 | XDH (0.79) | PTGS1PTGS2XDHHIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-20170298209-A1 | USE OF A QUINONE COMPOUND IN BUILDING MATERIALS | ARKION LIFE SCIENCES, LLC (US) | 2017-10-19 | — | — | US | disclosed |
| US-20150208657-A1 | USE OF QUINONE COMPOUND IN BUILDING MATERIALS | ARKION LIFE SCIENCES, LLC (US) | 2015-07-30 | — | — | US | disclosed |
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| WO-2012136782-A1 | METHOD OF DYEING OR MAKING UP KERATIN FIBRES USING A PIGMENT RESULTING FROM A 1,8-DIHYDROXYNAPHTHALENE DERIVATIVE, COMPOSITION CONTAINING THE PIGMENT AND THE PIGMENT | L'OREAL (FR) | 2012-10-11 | — | — | WO | disclosed |
| WO-2008100977-A2 | CARBAMATES THERAPEUTIC RELEASE AGENTS AS AMIDASE INHIBITORS | N.V. ORGANON (NL) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | PTGS1 1807/4885PTGS2 1948/4885XDH 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.